Therefore, if TIMP-1 can inhibit MPs and tumorigenicity, as has been shown for example in studies with murine melanoma cells (Walther and Denhardt, 1996), then why is increased expression in patients with cancer linked to a poor prognosis (Denhardt, 2000)? This evidence concerns the gene TIMP1 and cancer.